Poster abstracts
8. Therapy pathogenetic

P154 Early treatment with intravenous immunoglobulins (ET-IVIG trial) following the first attack of multiple sclerosis: rationale and study design
P155 Role of neutralizing antibodies (NABs) in IFNb treatment of MS patients
P156 Low-dose steroids reduce flu-like symptoms at the initiation of IFNb-1a in relapsing-remitting multiple sclerosis
P157 Selective in vivo depletion of TCR Vb5.2/5.3 expressing T cells in patients with multiple sclerosis
P158 Immunoablation with peripheral stem cell support in poor prognosis multiple sclerosis
P159 The danish national project of interferon-beta treatment in relapsing-remitting multiple sclerosis: a randomised open-label comparison of normal dose interferon-beta-1b and low dose interferon-beta-1a
P160 Efficacy of Azathioprine in R-R MS: MRI evaluation of brain lesions
P161 Tolerability of interferon beta treatment in a group of childhood multiple sclerosis
P162 Serial cytokine measures during the first 48? hours following the onset of interferon b-1a treatment
P163 Final results of pilot safety study of the combination of azathioprine and interferon b? 1A (Erazimus) in multiple sclerosis
P164 Is treatment with interferon beta-1a (Rebif?) associated with depression in multiple sclerosis?
P165 Tolerability and safety of betaferon combined with azathioprine in relapsing-remitting multiple sclerosis (RR MS)
P166 Tolerability of interferon beta-1a (IFNB-1a) in children with multiple sclerosis (MS)
P167 Long-term effect of I.V. pulse high dose methylprednisolone (HDMP) therapy on brain atrophy in relapsing-remetting multiple sclerosis (RRMS)
P168 IgM Enriched immunoglobulin (IgM-IVIg) for treatment of relapsing-remitting MS
P169 Prognosis of effects of b-interferon treatment according to clinical and genetic characteristics of MS patients
P170 Pulse intravenous cyclophosphamide therapy in rapidly deteriorating secondary progressive multiple sclerosis (SPMS)
P171 Do neutralizing antibodies reduce therapy benefit and quality of life in multiple sclerosis patients treated with interferon-beta 1a 44? mg subcutaneously?
P172 Delayed sleep phase syndrome (DSPS) associated with IFN-beta-1a (Avonex) treatment
P173 Antibodies to IFNb in RRMS patients during therapy: prevalence, kinetics, cross-reactivity and in vivo evaluation of the factors determining/enhancing IFNb immunogenicity
P174 Safety, pharmacokinetic (PK), and pharmacodynamic (PD) drug interaction study of antegren and interferon beta-1A (IFN b-1a, Avonex) in patients with relapsing remitting multiple sclerosis
P175 Combination therapy with the iron chelator dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis in lewis rats
P176 Interleukin-8 and rantes levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine (2-CDA)
P177 IVIG treatment in MS: preliminary report
P178 Two-year clinical, immunological and MRI follow-up after blood stem cell transplantation in 4? MS patients
P179 Neuroprotective effects of a-lipoic acid (Espa-lipon) in multiple sclerosis
P180 Immunological effects of intravenous immunoglobulin treatment in multiple sclerosis
P181 Does the impact of interferon b on disability in multiple sclerosis change over time?
P182 Development of multiple sclerosis in two patients on long-term azathioprine treatment
P183 Treatment of progressive multiple sclerosis with intravenous cyclophosmamide: analysis of 111? cases
P184 Treatment of relapsing-remitting multiple sclerosis patients with interferon beta-1a (Avonex?). A phase? IV, open label, multicentric study of two years duration
P185 Combined therapy with interferon beta-1b and azathioprine in multiple sclerosis: a pilot trial of 2? years duration
P186 Two cases of Bronchiolitis Obliterans with Organizing Pneumonia (BOOP) occuring during IFN-b1a (Avonex?) treated Multiple Sclerosis
P187 Evaluation of cardiac side effect in 103? MS? patients treated with mitoxantrone
P188 Use of Copaxone through the french "ATU" (temporary autorisation for use)
P189 Interferon b? 1-B treatment in relapsing-remitting multiple sclerosis: clinical and MRI results of 42? months experience
P190 Clinical and MRI efficacy of interferon b? 1-a once weekly in the treatment of relapsing-remitting multiple sclerosis: results of a two year follow up
P191 Subcutaneous interferon b-1a treatment in prevention of relapse and disability in relapsing-remitting multiple sclerosis
P192 Clinical outcome of mitoxantrone (MTX) treatment in secondary-progressive multiple sclerosis (SPMS) patients
P193 Onset of arthritis in patients with multiple sclerosis treated with interferon b-1a
P194 Quality of life in multiple sclerosis: influence of interferon b-1a (Avonex?) treatment
P195 Treatment of relapsing-remitting multiple sclerosis with weekly interferon? b-1a (Rebif?) -? First clinical results of the master study
P196 MRI baseline data of a multicenter double-blind, dose-comparison trial of 30? vs 60mcg rIFNb-1a (Avonex?) in patients with relapsing remitting multiple sclerosis

CONGRES ECTRIMS
6 - 9 septembre 2000
Toulouse

Retour au sommaire
 Lectures
Orals
Posters
Recherche par nom d'auteur
MASSON EDITEUR